This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Berrigan, D. Articles by Ballard-Barbash, R. Search for Related Content PubMed PubMed Citation Articles by Berrigan, D. Articles by Ballard-Barbash, R.

Serum Levels of Insulin-like Growth Factor-I and Insulin-like Growth Factor-I Binding Protein-3: Quality Control for Studies of Stored Serum

¹ National Cancer Institute, Bethesda, Maryland; ² Pathology Department, Baylor University Medical Center, Dallas, Texas; and ³ Center for Disease Control, National Center for Health Statistics, Hyattsville, Maryland

Requests for reprints: David Berrigan, Applied Research Program, Division of Cancer Control and Population Sciences, National Cancer Institute, Room 4095B, Executive Plaza North MSC 7344, Bethesda, MD 20892-7344. Phone: 301-451-4301; Fax: 301-435-3710. E-mail: berrigad{at}mail.nih.gov

The insulin-like growth factor (IGF) axis, particularly IGF-I and IGF binding protein-3 (IGFBP-3), has been the subject of much attention because of its role in juvenile growth and their association with cancers at several sites. However, epidemiologic studies of IGF-I and IGFBP-3 have had mixed results and several authors have speculated that quality control (QC), sample storage history, and other methodologic concerns could play a role in this heterogeneity. This article documents the results of storage history and QC efforts for a study of IGF-I and IGFBP-3 in 6,226 serum samples from the National Health and Nutrition Examination Survey III (NHANES III). The study was carried out on site at Diagnostic Systems Laboratories in Webster, Texas, using the IGF-I ELISA (DSL 10-5600) and the IGFBP-3 immunoradiometric assay (DSL 6600). A run-in study of assay performance suggested that plates, days, and weeks significantly affected the variance of both assays. Analysis of samples with different storage histories also indicated strong effects of storage history. Serum samples disbursed to laboratories for measurement of diverse analytes and then returned for storage showed reductions in serum IGF-I level averaging 43% and reductions in IGFBP-3 of 25% compared with samples shipped immediately to the repository for long-term storage at –80°C. Therefore, the main study was carried out using samples that had been shipped directly to the National Center for Health Statistics/NHANES collection center for storage. Laboratory analyses of NHANES III and QC samples were carried out over 10 months. QC was monitored through repeated testing of blood samples from six individuals, with two individuals tested twice on each plate. Assay performance was stable over the entire study and coefficients of variation averaged 2% to 3% within plates and 14% for IGF-I and 11.5% for IGFBP-3 over the entire study. Coefficients of variation varied significantly among individual QC subjects, ranging from 12.3% to 17.6% for IGF-I and 8.9% to 12.8% for IGFBP-3. Based on Levy-Jennings plots, 5% of the plates used for IGF-I in the main study were out of compliance. Finally, location on a plate had small but significant effects on IGF-I level. Together, these results highlight the need for care in large studies of putative biomarkers for cancer risk and illustrate some probable sources of heterogeneity in past epidemiologic studies of the IGF axis and cancer. (Cancer Epidemiol Biomarkers Prev 2007;16(5):1017–22)

This article has been cited by other articles:

				S. Saydah, B. Graubard, R. Ballard-Barbash, and D. Berrigan Insulin-like Growth Factors and Subsequent Risk of Mortality in the United States Am. J. Epidemiol., September 1, 2007; 166(5): 518 - 526. [Abstract] [Full Text] [PDF]